Shannon L Maude Selected Research

Shannon L Maude Research Topics

Disease

42	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 02/2024 - 08/2012
18	Cytokine Release Syndrome 01/2023 - 06/2013
16	Neoplasms (Cancer) 01/2023 - 02/2005
9	Leukemia 01/2023 - 10/2012
4	Residual Neoplasm 02/2024 - 12/2020
3	Infections 01/2023 - 01/2020
3	Sepsis (Septicemia) 01/2022 - 02/2014
3	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2022 - 06/2013
3	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 01/2016
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2021 - 11/2017
3	Critical Illness (Critically Ill) 10/2020 - 01/2016
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022 - 01/2018
2	cell-associated neurotoxicity 01/2022 - 12/2020
2	Fever (Fevers) 10/2021 - 02/2017
2	Bites and Stings (Sting) 01/2018 - 06/2013
2	Hyperferritinemia 02/2017 - 06/2013
1	COVID-19 01/2023
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2022
1	Lymphoma (Lymphomas) 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Down Syndrome (Down's Syndrome) 01/2022
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2021
1	Central Nervous System Diseases (CNS Diseases) 10/2021
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2020
1	Philadelphia Chromosome 01/2019
1	Glucocorticoid Receptor Deficiency 01/2019
1	Multiple Myeloma 01/2018
1	Respiratory Insufficiency (Respiratory Failure) 02/2017
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 02/2017
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2017
1	Body Weight (Weight, Body) 10/2014
1	Macrophage Activation Syndrome 03/2014
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2014
1	Cytopenia 06/2013
1	Carcinogenesis 04/2006
1	Genomic Instability 04/2006

Drug/Important Bio-Agent (IBA)

33	Chimeric Antigen ReceptorsIBA 12/2023 - 10/2014
22	tisagenlecleucelIBA 02/2024 - 10/2014
5	tocilizumab (atlizumab)FDA Link 01/2022 - 10/2014
5	CytokinesIBA 10/2020 - 06/2013
4	AntibodiesIBA 01/2022 - 06/2013
3	blinatumomabIBA 01/2022 - 06/2013
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2016
3	Interleukin-6 (Interleukin 6)IBA 01/2022 - 03/2014
3	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 01/2018
2	EmapalumabIBA 01/2023 - 01/2022
2	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2018
2	siltuximabIBA 01/2022 - 01/2016
2	CD19-specific chimeric antigen receptorIBA 01/2020 - 01/2016
2	Cytokine Receptors (Cytokine Receptor)IBA 01/2019 - 08/2012
2	Phosphotransferases (Kinase)IBA 01/2019 - 08/2012
2	CD19 AntigensIBA 12/2015 - 12/2014
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 04/2006 - 02/2005
1	Oxygen (Dioxygen)IBA 01/2023
1	Prostate-Specific Antigen (Semenogelase)IBA 01/2022
1	GlucocorticoidsIBA 01/2022
1	Blood Proteins (Serum Proteins)IBA 01/2022
1	ProteomeIBA 01/2022
1	Methylprednisolone FDA LinkGeneric 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022
1	Inotuzumab OzogamicinIBA 01/2022
1	Anaplastic Lymphoma KinaseIBA 01/2022
1	Death Domain ReceptorsIBA 01/2020
1	Immunoglobulin G (IgG)IBA 01/2020
1	AntigensIBA 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019
1	daratumumabIBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	Ferritins (Ferritin)IBA 02/2017
1	Surface Antigens (Surface Antigen)IBA 01/2017
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2016
1	EpitopesIBA 12/2015
1	InterferonsIBA 03/2014
1	InterleukinsIBA 03/2014
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 06/2013
1	Sirolimus (Rapamycin)FDA Link 10/2012
1	ruxolitinibIBA 10/2012

Therapy/Procedure

31	Therapeutics 12/2023 - 04/2006
11	Immunotherapy 01/2022 - 01/2016
8	Drug Therapy (Chemotherapy) 01/2024 - 02/2005
3	Critical Care (Surgical Intensive Care) 01/2023 - 02/2014
1	Secondary Prevention 02/2024
1	Castration 01/2022
1	Retreatment 01/2021
1	Artificial Respiration (Mechanical Ventilation) 02/2017